Bio-Manufacturing Market Size, Share, Growth, Trends, and Global Industry Analysis: By Workflow Type (Upstream Biomanufacturing Workflow, Single-Use Upstream Biomanufacturing Workflow, and Downstream Biomanufacturing Workflow), By Application (Monoclonal Antibodies, Vaccines, Hormones, and Recombinant Proteins), By End User (Biopharmaceutical Companies, Research Institutions, and CMOs/CDMOs, Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs), By Region Forecast 2019-2030

Bio-Manufacturing Market size was valued at USD x million in 2023 and is poised to grow at a  CAGR of x% from 2024 -2030.  The manufacturing side of the biotechnology sector is known as biomanufacturing. It is the process of producing goods using living systems, like plant, animal, or microbe cells. These cells of living organisms can naturally be developed but, more often than not, are genetically engineered to produce the material of interest. Biomanufacturer biomolecules include proteins and nucleic acids used in pharmaceuticals, food industry enzymes, and the bacteria's capacity for biodegradable bioplastics during growth. Some of the most critical factors driving the market are increased demand for biopharmaceuticals, advancements in technology, a favorable regulatory environment, and increased investments.

For instance, revenue from Moderna, Pfizer/BioNTech, and Johnson & Johnson vaccines fetched almost USD 31 billion in 2021; the reputation for mRNA vaccines and the expedited regulatory processes have caused a boom in vaccine sales. However, market growth is limited by high costs of manufacturing factors, regulatory challenges, risk of supply chain disruptions, and ethical and safety considerations. High growth in emerging markets, novel therapies, partnerships and collaborations, biosimilar growth, and developments in manufacturing technologies provides huge opportunity for the market. Other aspects of market trends include personalized medicine, automation and digitalization, initiatives for sustainability, combination of advanced therapies, and regenerative medicine.

Bio-Manufacturing Market Key Developments:

• In April 2020, Akron Biotech purchased Sarasota, Florida-based Cambryn Biologics. The building is a state-of-the-art biomanufacturing facility.
• In Febuary 2020, In order to aid the pharmaceutical and biotech industries pace medical therapies, Honeywell International Inc. partnered with Bigfinite, Inc. to contribute to process automation and controls technologies. Bigfinite's AI, data analytics, and machine learning platform will be utilized in this partnership.